Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis.
The prevalence of antibody to hepatitis C virus (anti-HCV) among 101 uremic patients receiving continuous ambulatory peritoneal dialysis (CAPD) was evaluated using a synthetic peptide-based HCV antibodies enzyme immunoassay. Thirty (29.7%) were found anti-HCV positive. This is significantly higher than 500 unselected paid blood donors (4.2%, P less than 0.0001). Among CAPD patients, anti-HCV positivity was found more frequently in patients who had received frequent and longer duration of hemodialysis previously (40.4% vs. 20.4%, P less than 0.05). These findings suggest that hemodialysis patients have a higher risk of HCV infection. At present, CAPD may be a suitable way to reduce the incidence of HCV infection in uremic patients.
Ng
Y Y
YY
Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Lee
S D
SD
Wu
S C
SC
Yang
W C
WC
Chiang
S S
SS
Huang
T P
TP
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D006509:Hepatitis B / Q000453:epidemiology; D006515:Hepatitis B virus / Q000276:immunology; D006526:Hepatitis C / Q000453:epidemiology*; D018937:Hepatitis C Antibodies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D013624:Taiwan / Q000453:epidemiology; D014511:Uremia / Q000150:complications*
D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies